Ecarin modified rotational thrombelastometry: A point-of-care applicable alternative to monitor the direct thrombin inhibitor argatroban

Wiener Klinische Wochenschrift

Volumn 125, Issue 5-6, 2013, Pages 156-159

  Schaden, Eva ^a   Schober, Andreas ^a   Hacker, Stefan ^a   Kozek Langenecker, Sibylle ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Evangelisches Krankenhaus Vienna   (Austria)

Author keywords

Anticoagulants; Argatroban; Blood coagulation tests; Drug; Ecarin; Monitoring; Prothrombin activation fragments; Thrombelastography

Indexed keywords

ARGATROBAN; ECARIN; ANTITHROMBIN; FIBRINOLYTIC AGENT; PIPECOLIC ACID DERIVATIVE; PROTEINASE;

ARTICLE; BLOOD CELL COUNT; BLOOD CLOTTING TIME; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MONITORING; ECARIN MODIFIED THROMBELASTOMETRY; FEMALE; HEMATOLOGICAL PROCEDURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NORMAL HUMAN; ROTATIONAL THROMBELASTOMETRY; BLOOD CLOTTING; HOSPITAL INFORMATION SYSTEM; METHODOLOGY; THROMBOELASTOGRAPHY;

ANTITHROMBINS; BLOOD COAGULATION; DRUG MONITORING; ENDOPEPTIDASES; FIBRINOLYTIC AGENTS; HUMANS; PIPECOLIC ACIDS; POINT-OF-CARE SYSTEMS; THROMBELASTOGRAPHY;

EID: 84884806057     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-013-0327-1     Document Type: Article

References (15)

1. Warkentin TE, Greinacher A, Koster A, Lincoff AM, American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest. 2008;133(Suppl 6):340-80.
2. Schaden E, Kozek-Langenecker SA. Direct thrombin inhibitors: pharmacology and application in intensive care medicine. Int Care Med. 2010;36:1127-37.
3. Luddington RJ. Thrombelastography/thrombelastometry. Clin Lab Haematol. 2005;27:81-90.
4. Kozek-Langenecker SA. Management of massive operative blood loss (review). Minerva Anestesiol. 2007;73:401-15.
5. Mittermayr M, Margreiter J, Velik-Salchner C, Klingler A, Streif W, Fries D, et al. Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem?): an in vitro study. Br J Anaesth. 2005;95:310-6.
6. Schaden E, Schober A, Hacker S, Spiss C, Chiari A, Kozek-Langenecker S. Determination of enoxaparin with rotational thrombelastometry using the prothrombinaseinduced clotting time reagent. Blood Coagul Fibrinolysis. 2010;21:256-61.
7. Engström M, Rundgren M, Schött U. An evaluation of monitoring possibilities of argatroban using rotational thrombelastometry and activated partial thromboplastin time. Acta Anaesth Scand. 2009;1:1-6.
8. Swan S, Hursting M. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318-29.
9. Sucker C, Zotz RB, Görlinger K, Hartmann M. Rotational thrombelastometry for the bedside monitoring of recombinant hirudin. Acta Anaesth Scand. 2008;52:358-62.
10. Francis JL, Hursting MJ. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents. Blood Coagul Fibrinolysis. 2005;16:251-7.
11. Wenzel C, Stoiser B, Locker G, Laczika K, Quehenberger P, Kapiotis S, et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med. 2002;30:763-70.
12. Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost. 2007;98:234-42.
13. Walenga JM, Fasanella AR, Iqbal O, Hoppensteadt DA, Ahmad S, Wallis DE, et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Haemost. 1999;25(Suppl 1):61-6.
14. Siegmund R, Boer K, Poeschel K, Wolf G, Deufel T, Kiehntopf M. Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients. Thromb Res. 2008;123:159-65.
15. Lange U, Nowak G, Bucha E. Ecarin Chromogenic Assay- a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb. 2003;33:184-91.